An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.

J Med EconJul 14, 2026 (epub)
Clinical ResearchOncology (Medical)

Toby A Eyre, Leyla Mohseninejad, Lianne Barnieh et al.

✦ AI-curated · Sources linked

In 30 seconds

This study conducted an unanchored matching-adjusted indirect comparison to evaluate the efficacy of zanubrutinib versus ibrutinib in patients with relapsed/refractory mantle-cell lymphoma (R/R MCL). The analysis included individual patient data from zanubrutinib trials (n=118) and pooled data from ibrutinib trials (n=370). Results indicated that zanubrutinib significantly improved progression-free survival (HR=0.63) and overall survival (HR=0.46) compared to ibrutinib.

Key findings

  • Zanubrutinib showed a hazard ratio of 0.63 for progression-free survival compared to ibrutinib.
  • Overall survival was significantly better with zanubrutinib, with a hazard ratio of 0.46.
  • Statistical significance was achieved with p-values of 0.0044 for progression-free survival and 0.0005 for overall survival.

Why it matters

Understanding the comparative efficacy of treatments for relapsed/refractory mantle-cell lymphoma is crucial for optimizing patient outcomes. This study provides insights that may influence treatment decisions in clinical practice.

Source

PubMed · PMID 42452801

Published in J Med Econ. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchPreventive Medicine / Public Health

2025 National Guidelines on the Mediterranean Diet: Executive Summary of a Joint Report by Italian Scientific Societies and the National Institute of Health Task Force on Clinical Practice Guidelines.

This systematic review and practice guideline, developed by a multidisciplinary panel using NUTRIGRADE, assessed Mediterranean diet evidence across nine health domains and one economic domain.

Nutr RevNov 12, 2026Read summary
Clinical ResearchOrthopedic Surgery

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.

This multicenter randomized comparative-effectiveness noninferiority trial compared 30 days of aspirin, warfarin, or rivaroxaban for VTE prophylaxis after elective total hip or knee arthroplasty.

N Engl J MedNov 12, 2026Read summary
Clinical ResearchAnesthesiology

Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trial.

This multicentre, randomised, double blind, placebo controlled trial assessed whether withholding ACE inhibitors or ARBs on the morning of surgery reduces perioperative hypotension in older adults undergoing non-cardiac…

BMJNov 11, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.